Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Список исп. литературыСкрыть список 1. Wolfe F, Smythe HA, Yunus MB et al. The american college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 160–72. 2. Mease P. Fibromyalgia syndrome. Review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005; 32 (Suppl. 75): 6–21. 3. Robinson RL, Birnbaum HG, Morley MA et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003; 30: 1318–25. 4. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 2001; 5: 320–9. 5. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355–474. 6. Nielsen LA, Henriksson KG. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain inhibition. Best Pract Res Clin Rheumatol 2007; 21: 465–80. 7. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000; 12 (Suppl. 1): 2–19. 8. Jann MW, Slade JH. Antidepressant agents for the treatment of chronic pain and depression. Pharmacother 2007; 27: 1571–87. 9. Arnold LM, Lu Y, Crofford LJ et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974–84. 10. Arnold LM, Rosen A, Pritchett LY et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5–15. 11. Russell IJ, Mease PJ, Smith TR et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder. Results from a 6-month randomized, double-blind, placebo-controlled, fixed-dosed trial. Pain 2008; 136: 432–44. 12. Chappell AS, Bradley LA, Wiltse C et al. A six-month, double-blind, placebo-controlled randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008; 1: 91–102. 13. Cleeland CS, Ryan KM. Pain assessment: global use of the brief inventory. Ann Acad Med Singapore 1994; 23: 129–38. 14. Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacol, Revised. Publication Adm. 76-338. Washington: US Dep of Health, Education, and Welfare 1976. 15. Smets EM, Garssen B, Bonke B, De Haes JC. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39: 315–25. 16. Fava M, Graves LM, Benazzi F et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiat 2006; 67: 1754–9. 17. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893–7. 18. Beck AT, Steer RA, Carbin MG. Psychometric properties of the beck depression inventory: 25 years of evaluation. Clin Psychol Rev 1988; 8: 77–100. 19. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston. The Health Institute. New England Med Center 1993. 20. Mallinckrodt CH, Sanger TM, Dube S et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiat 2003; 53: 754–60. 21. Arnold LM, Crofford LJ, Mease PJ et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008; 73: 114–20. 22. Hudson JI, Arnold LM, Bradley LA et al. What makes fibromyalgia patients feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: a pooled analysis of 4 randomized placebo-controlled trials of duloxetine. J Rheumatol 2009; 36: 2517–22. 23. Fava M, Iosifescu DV, Pedrelli P, Baer L. Reliability and validity of the Massachusetts General Hospital cognitive and physical functioning questionnaire. Psychother Psychosom 2009; 78: 91–7. 24. Seidenberg M, Haltiner A, Taylor MA et al. Development of a multiple ability self-report questionnaire. J Clin Exp Neuropsychol 1994; 16: 93–104. 25. Mease PJ, Clauw DJ, Gendreau RM et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009; 36: 398–409.